{
    "Trade/Device Name(s)": [
        "ATTEST Drug Screen Cup",
        "ATTEST Drug Screen Dip Card"
    ],
    "Submitter Information": "Advin Biotech, Inc.",
    "510(k) Number": "K182123",
    "Predicate Device Reference 510(k) Number(s)": [
        "K122809"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG",
        "DKZ",
        "DIO",
        "DJC"
    ],
    "Summary Letter Date": "March 29, 2019",
    "Summary Letter Received Date": "February 12, 2019",
    "Submission Date": "February 7, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.3650",
        "21 CFR 862.3100",
        "21 CFR 862.3250",
        "21 CFR 862.3610"
    ],
    "Regulation Name(s)": [
        "Opiate test system",
        "Enzyme Immunoassay, Amphetamine",
        "Enzyme Immunoassay, Cocaine and cocaine metabolites",
        "Methamphetamine Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "6-Acetylmorphine",
        "Amphetamine",
        "Barbiturates",
        "Benzodiazepines",
        "Buprenorphine",
        "EDDP",
        "Cocaine",
        "Ecstasy",
        "Methamphetamine",
        "Marijuana",
        "Methadone",
        "Opiates",
        "Oxycodone",
        "Phencyclidine",
        "Propoxyphene",
        "Tricyclic Antidepressants"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow immunoassay",
        "Immunochromatographic assay"
    ],
    "Methodologies": [
        "Qualitative detection",
        "Competitive binding"
    ],
    "Submission Type(s)": [
        "Assay",
        "Dip Card",
        "Cup"
    ],
    "Document Summary": "FDA 510(k) summary for ATTEST Drug Screen Cup and Dip Card, qualitative rapid lateral flow immunoassays for detection of multiple drugs of abuse in human urine.",
    "Indications for Use Summary": "Intended for prescription use as rapid lateral flow immunoassays for qualitative detection of drugs of abuse and/or their metabolites (up to 16 analytes in any combination) in human urine; results are preliminary and require confirmatory testing by alternative chemical methods.",
    "fda_folder": "Toxicology"
}